



Steven D. Barrett

PARTNER

Co-Chair, Technology Transactions and Licensing Practice Group

BOSTON

+ 1 617 526 6238

STEVEN.BARRETT@WILMERHALE.COM

Steve Barrett, co-chair of the Technology Transactions and Licensing Practice Group, advises a variety of life sciences and technology companies regarding the structuring, negotiation and drafting of agreements for a broad range of technology transactions, including technology acquisition, license, strategic alliance and joint venture transactions, and related research, development, supply, marketing, distribution and services agreements. Mr. Barrett regularly represents entrepreneurs, early-stage and established life sciences and technology companies and large commercial enterprises.

Learn more about Mr. Barrett's practice and how he can support your startup on WilmerHaleLaunch.com.

Community Involvement

Mr. Barrett serves on the board of directors of The Political Asylum/Immigration Representation (PAIR) Project. Mr. Barrett has also successfully represented, on a pro bono basis, a number of persons who have fled persecution in other countries and sought political asylum in the United States.

Mr. Barrett served on active duty as a US naval officer from 1989 to 1992. His assignments included division officer tours in USS Hoel (DGG-13) and USS Waddell (DDG-24), and he qualified as a surface warfare officer and was awarded the Navy Achievement Medal.

Solutions

Cross-Border Transactions

Emerging Company and
Venture Capital

Life Sciences

Experience

- Mr. Barrett has recently represented:
 - Adimab in its antibody platform licensing agreements with GSK (2013), Biogen Idec (2013), Novo Nordisk (2013) and Merck (2015)
 - Agios Pharmaceuticals in its Chinese territory collaboration and license agreement for Ivosidenib with CStone Pharmaceuticals (2018)
 - Agios Pharmaceuticals in its licensing agreement for metabolic immuno-oncology inhibitors with Aurigene Discovery Technologies Limited (2017)
 - Agios Pharmaceuticals in its metabolic immuno-oncology collaboration with Celgene (2016)
 - Alnylam in its Asian territory TTR-mediated amyloidosis RNAi collaboration with Genzyme (2012)
 - Alnylam in its prior collaborations with Medtronic (2007), Takeda (2008), Cubist (2009) and GSK (2011)
 - Concert Pharmaceuticals in its multi-program deuterium-modified drug collaboration with Celgene (2013)
 - Concert Pharmaceuticals in its prior collaborations with GSK (2009), Avanir Pharmaceuticals (2012) and Jazz Pharmaceuticals (2013)
 - Dendreon in its \$125 million sale of its royalty interest in VICTRELIS™ (boceprevir) to CPPIB Credit Investments (2011)
 - Editas Medicine in its licensing agreement for base editing technology with Beam Therapeutics (2018)
 - Editas Medicine in its strategic alliance and option agreement with Allergan (2017)
 - Editas Medicine in its licensing of CRISPR technologies from the Broad Institute, MIT, Harvard and other academic institutions (2016)
 - Epizyme in its combination clinical trial collaboration with Genentech (2016)
 - Epizyme in its restructuring of its collaboration with Celgene (2015)
 - Epizyme in its reacquisition of EZH2 inhibitor oncology program rights from Eisai (2015)
 - Epizyme in its prior collaborations with GSK (2011), Eisai (2011), Celgene (2012), Roche Molecular Systems (2012) and Abbott Molecular (2013)
 - Idera Pharmaceuticals in its companion diagnostic development agreement with Abbott Molecular (2014)
 - Lexicon in its worldwide collaboration and licensing agreement for sotagliflozin with Sanofi (2015)
 - Lexicon in its ex-US and Japan licensing agreement for telotristat etiprate with

- Ipsen (2014)
- MacroGenics in its anti-PD-1 monoclonal antibody collaboration with Incyte (2017)
 - Merrimack Pharmaceuticals in its >\$970 million ex-US license and collaboration agreement with Baxter (2014)
 - Merrimack in its prior collaborations with Sanofi-Aventis (2009), PharmaEngine (2011) and Actavis (2013)
 - Mitobridge in its \$730 million mitochondria-related disease collaboration with Astellas (2013)
 - Nosocomial Vaccine Corporation in its collaboration with Astellas, Affinivax and University of Maryland (2015)
 - Ophthotech in its >\$1 billion ex-US licensing and commercialization agreement for FOVISTA™ with Novartis (2014)
 - Ophthotech in its \$175 million royalty financing arrangement with Novo A/S (2013)
 - Potenza Therapeutics in its immuno-oncology collaboration with Astellas (2015)
 - Spark Therapeutics in its ex-US licensing and commercialization agreement for LUXTURNA™ with Novartis (2018)
 - Spark Therapeutics in its synthetic vaccine particles licensing transaction with Selecta Biosciences (2016)
 - Spark Therapeutics in its hemophilia B gene therapy collaboration with Pfizer (2014)
 - Spark Therapeutics in its prior licensing agreements with Genable Technologies (2014) and Children's Hospital of Philadelphia (2013)
 - Summit Therapeutics in its Latin America license and commercialization agreement for its ridinilazole antibiotic for the treatment of Clostridium difficile infection with Eurofarma Laboratórios (2017)
 - Summit Therapeutics in its Duchenne muscular dystrophy collaboration with Sarepta Therapeutics (2016)
 - Vertex Pharmaceuticals in its collaboration and licensing agreement to develop ENaC inhibitors for cystic fibrosis and other pulmonary diseases with Parion Sciences (2015)
 - Vividion Therapeutics in its small molecule ubiquitin proteome collaboration with Celgene (2018)
 - vTv Therapeutics in its Pacific Rim territory licensing agreement for vTv's PDE4 inhibitor program with Newsoara Biopharma Co. (2018)
 - vTv Therapeutics in its global licensing agreement for vTv's PPAR-delta agonist program with Reneo Pharmaceuticals (2017)

Recognition

- Selected by his peers for inclusion in the 2019 edition of the *Best Lawyers in America* in the Biotechnology and Life Sciences Practice category

- Recognized as a leader in life sciences in the 2015 and 2016 editions of *Who's Who Legal*
- Recommended in the 2016, 2017 and 2018 editions of *The Legal 500 United States* for his work in M&A/Corporate and Commercial as well as Media, Technology and Telecoms: Outsourcing and Transactions
- Recognized for his practice and named a "Life Sciences Star" in the 2012-2018 editions of *LMG Life Sciences* and named to its 2017 awards shortlist for Finance & Transactional Attorney of the Year: Licensing & Collaboration. He was also awarded one of five Finance and Transactional Impact Cases of the Year by *LMG* for counseling Editas Medicine in its licensing and collaboration with Allergan.
- Recognized in each edition of the *PLC Cross-border Life Sciences Handbook* in the USA Commercial and Partnering category since the 2006/07 edition; listed as Leading in this category in the 2009/10 and 2011/12 editions
- Named "Massachusetts *Super Lawyer*" in the areas of intellectual property and business/corporate law in the 2014-2016 editions of *Boston Magazine*
- Named a "Massachusetts *Super Lawyers Rising Star*" in intellectual property law in the 2005 and 2006 issues of *Boston Magazine*

Credentials

EDUCATION

JD, University of Michigan Law School, 1996

cum laude

MBA, University of Michigan, 1996

with High Distinction

SB, Mechanical Engineering, Massachusetts Institute of Technology, 1989

ADMISSIONS

Massachusetts

Michigan

United States Patent and Trademark Office